CXCL9 and melanoma: Some clinically available anticancer drugs including ipilimumab (an anti-CTLA-4), doxorubicin, and dacarbazine have also been shown to upregulate the expression levels of CXCL9, CXCL10, and CXCL11 in the tumor tissues of patients with melanoma and breast cancer, possibly contributing to their therapeutic effects [218,219,220].